Introduction
The ability to metastasis is the most fearsome aspect of cancer and most cancer deaths are the sequel of metastatic diseases rather than primary tumor growth. In order to form overt metastases, a cell must complete the metastatic cascade, a series of well-defined steps including local invasiveness, intravasation, circulation, adhesion and extravasation, survival, proliferation and angiogenesis [1] . Within this multistep process, adhesive ability of metastatic tumor cells is a critical factor in extravasation and formation of new tumor foci [2] [3] [4] [5] [6] . Cancer continues to represent the largest cause of mortality in the world and claims over 6 million lives every year [7] . An extremely promising strategy for the management of cancer today is chemoprevention, which is defined as the use of synthetic or natural agents (alone or in combination) to block the development of cancer in humans [8, 9] . Studies on the pharmacological mechanisms and the search for new anticancer and anti-metastasis drugs are necessary and hold great interest for scientists. The compound GLB, (2''S,3aR, 6S,7aR)-3''-acetyl-3a,7a-dihydro-2,2,2',2'-tetramethyl-5''-(4-bromophenyl)-spiro{spiro [1,3- pound could inhibit the growth of S180 carcinoma in ICR and LACA mice. However, its precise function and mechanism of action on tumor and tumor metastasis have not been determined in full. In the present study, we investigated the effect of GLB on tumor metastasis in mice treated orally and examined its effect on the adhesion of tumor cells in vitro to clarify its possible mechanism of anti-metastasis.
Materials and methods
Cell culture Human umbilical vein endothelial cells (HUVEC) were isolated by collagenase I (1 g/L, Invitrogen, USA) digestion of umbilical veins from undamaged sections of fresh cords. HUVEC were grown in Medium 199 (Gibco, USA) supplemented with 20% heat-inactivated fetal bovine serum (FBS), 20 mg/L endothelial cell growth supplement (ECGS, Sigma, USA), 1×10
5 IU/L penicillin, 100 mg/L streptomycin and 2 mmol/L L-glutamine. Replicate cultures were obtained by trypsinization and cells of passages 3-6 were used in the experiments. The identification of HUVEC was confirmed by their polygonal morphology and by detecting their immunoreactivity for factor VIII-related antigens [10] . Human prostate carcinoma cells (PC-3M) were cultivated in RPMI-1640 containing 10% heat-inactivated FBS, 1×10
5 IU/ L penicillin and 100 mg/L streptomycin in a humidified incubator with 5% CO 2 in air at 37 °C.
Assay of PC-3M cell adhesion to HUVEC PC-3M cells were labeled with CFDA (carboxyfluorescein diacetate, Sigma, 100 mg/L) for 30 min at 37 °C [11] . Cells were washed twice with phosphate-buffered saline (PBS) to remove residual fluorescent dye. The viability of the cells was not compromised by this labeling protocol, as indicated by Trypan blue exclusion.
HUVEC were cultured to confluence in 96-well dishes coated with 2% gelatin. Confluence was confirmed using microscopy and CFDA-labeled PC-3M cells were washed and resuspended in culture medium. One hundred microliters of the tumor-cell suspension (about 1×10 4 cells) was added to HUVEC monolayers in 96-well dishes and co-cultured for 30 min at 37 °C. At the end of the experiment, the wells were washed twice with PBS to remove non-adhering PC-3M cells. The adherent cells were counted under a fluorescence microscope using an excitation wavelength of 492 nm, using five fields in each well [10] . Assay of PC-3M cell adhesion to laminin The 96-well plates were coated with laminin (extracted by the Department of Cytobiology, Peking University) and incubated in RPMI-1640 containing 0.02% bovine serum albumin (BSA) for 15 min at 37 °C. In a total volume of 100 µL RPMI-1640,
8×10
4 PC-3M cells were added to each well and incubated for 4 h at 37 °C in the presence of GLB. After removing unattached cells with two washes with PBS, the attached cells were inccubated with 20 µL sterile MTT dye (Sigma) for a further 2 h at 37 °C. The medium was then removed, and 100 µL dimethyl sulfoxide (Me 2 SO) was added and mixed thoroughly. Spectrometric absorbance at 540 nm (for formazan dye) and 690 nm (as background level) was measured using a microplate reader (Bio-Rad, USA) [12] . Proliferation assay PC-3M cells (1×10 4 cells/well) were cultured in 24-well plates and incubated for 1, 2, 3, 4, 5, and 6 d in the presence of GLB at various concentrations. The medium with GLB was changed every 48 h. After incubation the cells were harvested and washed with PBS. The number of viable cells in each well was then determined and counted using the Trypan blue exclusion assay [13] . Lewis lung carcinoma in vivo model Female C57BL/6 mice weighing 18 g-20 g were used and purchased from the Experimental Animal Center of Peking University (Grade II, Certificate No 11-00-0004). Lewis lung carcinoma (provided by the Chinese Medical Science Institute) was maintained in C57BL/6 mice by subcutaneous injection in the axillary's region of 0.2 mL of homogenized tumor tissue [tumor tissue (g): 0.9% sodium chloride (mL), 1:3] prepared from donors similarly inoculated for experimental tumor transplantation [14] . Metastasis in vivo GLB was suspended in 0.5% (w/v) sodium carboxyl methylcellulose (CMC-Na) in distilled water and administered orally for 27 d (25, 50, and 100 mg·kg -1 · d -1 ) from the next day of tumor cell injection. After the d 6, the tumor volumes of mice were measured every 3 d. At the d 28, the mice were killed and the lungs and primary tumors were removed and weighed. The number of metastasized pulmonary colonies was counted and lung tissues were fixed in formalin for further analysis. The inhibitory rate of lung metastasis (%) was calculated using the equation (W model -W treatment )/(W model -W control )×100%, where W is lung wet weight [14] [15] [16] . Pathological evaluation of lung The fixed lung tissue samples were embedded in paraffin, sectioned at 5 µm and stained with hematoxylin and eosin to evaluate alveolar integrity by counting area percentage of alveolus in lung. A total of 5 fields from each lung sample were screened randomly; the mean value was accepted as representative of the sample [17] .
Statistical analysis
The experimental results were expressed as mean±standard deviation (SD). Statistical analysis was carried out using one-way analysis of variance (ANOVA) followed by Dunnett's test with SPSS version 10.0. P<0.05 was considered to be statistically significant.
Results
Inhibitory effects of GLB on spontaneous metastasis of Lewis lung carcinoma in mice We investigated the effect of oral administration of GLB on the spontaneous metastasis of Lewis lung carcinoma. GLB at the dose of 100 mg/kg significantly reduced the number of pulmonary metastatic colonies of Lewis lung carcinoma cells (P<0.05). The inhibitory rate of colony formation was approximately 31%. During the drug treatment, we found neither body weight loss nor toxic death in the GLB-treated mice. In addition to a reduction in the number of lung colonies by GLB, the survival rate of mice treated with GLB was significantly higher than that of untreated mice bearing Lewis lung carcinoma (Table 1) . Although the mean weight and volume of the primary tumor in GLB-treated mice were less than those of vehicle-treated mice, there was no statistical difference (P>0.05, Table 1, Figure 2 ). (Figure 3) .
Effect of GLB on alveolar integrity in mice with
Inhibitory effects of GLB on metastatic adhesion function of tumor cells We evaluated the effects of GLB on the metastatic adhesion functions of tumor cells by examining its effect on PC-3M cell adhesion to endothelial monolayers and laminin. GLB, at the concentrations of 1×10 -5 mol/L and 10 -6 mol/L, inhibited significantly the adhesion of PC-3M cells to HUVEC (P<0.01, Figure 4 ). GLB at these concentrations also inhibited the attachment of PC-3M cells to the laminin (P<0.05, Figure 5 ). To clarify whether the inhibitory action on adhesion function could be due to a cytotoxic effect, GLB was tested for its effect on PC-3M cell proliferation ( Figure  6 ). GLB had no substantial effect on the growth of tumor cells after up to 5 d incubation. Until the latter period of cell growth (d 6 and 7), the proliferation of PC-3M cells treated with 1×10
-5 mol/L and 1×10 -6 mol/L GLB showed signs of a slight decrease.
Discussion
As has been demonstrated, the sequential process of micrometastasis formation by Lewis lung carcinoma includes single cells in the blood circulation escaping from the immune system, adhering to epithelial cells, migrating into the tissue, proliferating and making colonies in the lung [18] . Investigate the earliest events during micrometastasis formation is useful and could be simply applied for the estimation of anti-metastatic and anti-adhesive effects of various anticancer agents [12] . The antitumor activities of the derivatives of oxadiazoles, one-membered heterocycles, have been reported and are found to be related to their chelating abilities or non-polarity, which is essential to penetrate through intracellular sites [19] . These include the new 5-(2-amino-3-pyridyl)-2-thioxo-3H-1, 3,4-oxadiazole derivatives that have shown cytotoxic Figure 3 . Effect of GLB on alveolar integrity in mice with Lewis lung carcinoma cells. The area percentage of alveolus in lung tissue of normal C57BL/6 mice was almost 50% (A), and that in lung of mice bearing Lewis lung carcinoma (model) was decreased (B). Lung tissues of C57BL/6 mice bearing Lewis lung carcinoma treated with (C) 25 mg/kg, (D) 50 mg/kg and (E) 100 mg/kg GLB were significantly better than the model. Hematoxylin-eosin stain, ×100. (F activity against the cells of 4 human tumor cell lines [20] and 2, 5-disubstituted-1,3,4-oxadiazole compounds, which are potential anticancer agents [21] . The present study demonstrated that oral administration of GLB inhibited the spontaneous pulmonary metastasis of tumor cells in C57BL/6 mice and increased the survival rate. GLB significantly inhibited the adhesion by PC-3M cells without affecting cell proliferation in vitro. The present data suggest that GLB prevents tumor metastasis partly by inhibiting the metastatic adhesion of tumor cells.
Tumor cell adhesion to endothelial monolayers is a critical step in tumor metastasis [22] , as is laminin expression in endothelial cells, being one of the earliest extracellular matrix (ECM) proteins. Laminin interaction with the β-1 integrin has been shown to have an important role in the regulation of tumor-to-endothelial cell adhesion [10] . We demonstrated that GLB significantly inhibited the adhesion of tumor cells to laminin, using the same doses of GLB as had been found to inhibit adhesion of tumor cells to endothelial cells. This suggests that the anti-adhesion activity of GLB might be due to its effect on laminin, one of many other factors involved in adhesion.
β-1 Integrin is known to recognize many ECM proteins as ligands, such as laminin, collagen and fibronectin. Laminin has been identified as the most important of these ligands for β-1 integrin in the cell adhesion process [23, 24] . Whether GLB exerts its function through β-1 integrin or not is yet to be determined. In the present study, GLB showed no effect on the weight of the primary tumor site in C57BL/6 mice subcutaneously injected with a Lewis lung carcinoma tumor cell suspension (Table 1) . In a preliminary experiment where S180 carcinomas were implanted subcutaneously into ICR and LACA mice, GLB-treated mice (50 mg·kg -1 ·d -1 for 12 d, ip) showed a significant decrease in tumor weight, with inhibitory rates of 43% and 32% (tumor weight at d 12, mean±SD: 1.16±0.67 g vs 2.05 ± 0.64 g, P<0.01 for ICR mice; 1.81±0.68 g vs 2.65± 0.81 g, P<0.05 for LACA mice; n=10 mice). The different effects of GLB on these in vivo assay models may be dependent on the kind of tumor, the period of the experiment and route of administration. We speculate that there might be other mechanisms of action for GLB that require further study, including the relationship between its effects on tumor growth or metastasis and its inhibition of angiogenesis.
In conclusion, the compound GLB prevents tumor metastasis by inhibiting tumor adhesion. This suggests it has potential for future anti-metastatic development.
